Results 101 to 110 of about 12,660 (249)

EURL ECVAM Workshop on New Generation of Physiologically-Based Kinetic Models in Risk Assessment [PDF]

, 2017
The European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) Strategy Document on Toxicokinetics (TK) outlines strategies to enable prediction of systemic toxicity by applying new approach methodologies (NAM).
Bessems, J, Desalegn, A, Dorne, JL, Gosling, JP, Heringa, MB, Joossens, E, Klaric, M, Kramer, N, Loizou, G, Louisse, J, Lumen, A, Madden, JC, Paini, A, Patterson, EA, Proenca, S, Punt, A, Setzer, RW, Suciu, N, Tan, YM, Troutman, J, Worth, A, Yoon, M   +21 more
core   +2 more sources

Physiologically based pharmacokinetic modeling and simulation of topiramate in populations with renal and hepatic impairment and considerations for drug–drug interactions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 510-522, March 2025.
Abstract Topiramate (TPM) is a broad‐spectrum antiepileptic drug (AED) commonly prescribed for approved and off‐label uses. Routine monitoring is suggested for clinical usage of TPM in special population due to its broad side effect profile. Therefore, it is crucial to further explore its pharmacokinetic characteristics.
Shuqing Chen, Chaozhuang Shen, Yuchen Tian, Yuhe Peng, Jing Hu, Haitang Xie, Ping Yin   +6 more
wiley   +1 more source

Optimizing ribociclib dosing in breast cancer with brain metastasis patients using a physiologically based pharmacokinetic model

BMC Cancer
Objective This study aimed to determine the optimal dosing strategy for ribociclib (RIB) in patients with breast cancer and brain metastasis (BCBM) by using a developed and validated physiologically based pharmacokinetic (PBPK) model.
Chao Zhang, Shan Li, Jiawei Ren, Xiaohui Wen   +3 more
doaj   +1 more source

Application of Physiologically‐Based and Population Pharmacokinetic Modeling for Dose Finding and Confirmation During the Pediatric Development of Moxifloxacin

CPT: Pharmacometrics & Systems Pharmacology, 2019
Moxifloxacin is a widely used fluoroquinolone for the treatment of complicated intra‐abdominal infections. We applied physiologically‐based pharmacokinetic (PBPK) and population pharmacokinetic (popPK) modeling to support dose selection in pediatric ...
Stefan Willmann, Matthias Frei, Gabriele Sutter, Katrin Coboeken, Thomas Wendl, Thomas Eissing, Jörg Lippert, Heino Stass   +7 more
doaj   +1 more source

From PK/PD to QSP: Understanding the Dynamic Effect of Cholesterol-Lowering Drugs on Atherosclerosis Progression and Stratified Medicine [PDF]

, 2016
Current computational and mathematical tools are demonstrating the high value of using systems modeling approaches (e.g. Quantitative Systems Pharmacology) to understand the effect of a given compound on the biological and physiological mechanisms ...
Diaz-Zuccarini, V, Pichardo-Almarza, C
core  

SISO APP Searches in Lattices with Tanner Graphs

, 2011
An efficient, low-complexity, soft-output detector for general lattices is presented, based on their Tanner graph (TG) representations. Closest-point searches in lattices can be performed as non-binary belief propagation on associated TGs; soft ...
Ionescu, Dumitru Mihai, Zhu, Haidong
core   +1 more source

Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation [PDF]

, 2016
Adequate concentrations of efavirenz in the central nervous system (CNS) are necessary to suppress viral replication, but high concentrations may increase the likelihood of CNS adverse drug reactions.
Curley, Paul, Letendre, Scott, Liptrott, Neill J, Moss, Darren M, Owen, Andrew, Rajoli, Rajith KR, Siccardi, Marco   +6 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

EuroMix PBPK model for combined exposures

, 2019
In this paper documents the structure and default parameter values of the EuroMix PBPK model implemented in the MCRA platform for rats and humans. A version allowing apportionment of results by exposure routes is also described. Finally, the extensions needed to describe pharmacokinetic interactions between pairs or triplets of substance are discussed.
Bois, F.Y., Tebby, C., Brochot, C.
openaire   +1 more source

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source